Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A021806||Alliance||A Phase III Trial of Perioperative versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A151804||Alliance||Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011202||Alliance||A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy||Adult CIRB - Late Phase Emphasis||Available to Open|
|A071401||Alliance||Phase II Trial Of SMO/AKT/NF2 Inhibitors In Progressive Meningiomas With SMO/AKT/NF2 Mutations||Adult CIRB - Early Phase Emphasis||Available to Open|
|A221208||Alliance||Randomized Phase II Study: Corticosteroids and Bevacizumab vs. Corticosteroids and Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases||Cancer Prevention and Control CIRB||Available to Open|
|A031801||Alliance||A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (RADICAL)||Adult CIRB - Late Phase Emphasis||Available to Open|
|A031201||Alliance||Phase III Trial of Enzalutamide (NSC # 766085) Versus Enzalutamide; Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|A011203||Alliance||A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic; Estrogen Receptor Positive; HER2 Negative Breast Cancer||Adult CIRB - Early Phase Emphasis||Available to Open|
|A081105||Alliance||Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)||Adult CIRB - Late Phase Emphasis||Available to Open|
|EA9171||Alliance||Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease||Adult CIRB - Late Phase Emphasis||Available to Open|